![The primary goal of the Paradigm Registry is to accelerate tumor profiling based on disease biology. [iStock/LilliDay]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/307-218x150.jpeg "AI Algorithm Could Reduce Breast Cancer Mammogram False Positive Rate")
A new study by neuroscientists have reveals that an emerging image-quantifying technology called radiomics can be used to extract biomarkers from clinical brain MRI scans in stroke patients and estimate a patient’s relative “brain age.”
UCSF research confirms and expands links between sex-linked genetic variants and disorders such as autism spectrum disorder and heart failure.
A new mouse study by researchers at UT Southwestern (UTSW) reveals that scar-like cells that make up a large portion of malignant pancreatic tumors shield these cancers from immune attack and are derived from mesothelial cells that line tissues and organs.
Rutgers scientists have developed a test that identifies variants of the virus that causes COVID-19. This advance will be made freely available to other labs.
A deep learning model based on gene expression data can accurately predict whether a drug will adversely interact with other drugs.
The deal, which the companies say is a first of its kind, pairs a genomic sequencing and array technology leader with an investment firm to advance new drug targets through the development pipeline.
A protein called CDC7, which has been known to play an essential role early in the cell division process, can be switched to another protein called CDK1, a finding researchers at Weill Cornell Medicine and the Dana Farber Cancer Institute believe may lead to new cancer therapies.
The study shows that the group of boys overweight at age 8 had an increased risk of obesity-related cancer in adulthood. This applied particularly to those whose weight remained elevated at age 20.
Some people see no change after immunotherapy, but others develop serious problems in their lungs, bowel, and even skin during treatment. These side effects can be debilitating and even fatal.
The test is intended for adults age 45 and older who are not up to date with recommended screening guidelines, show no symptoms of CRC, and are at average risk for developing the diesase.
